Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.

被引：0

作者：

Fong, Peter C. C.

Retz, Margitta

Drakaki, Alexandra

Massard, Christophe

Berry, William R.

Romano, Emanuela

De Bono, Johann S.

Feyerabend, Susan

Appleman, Leonard Joseph

Conter, Henry Jacob

Sridhar, Srikala S.

Shore, Neal D.

Linch, Mark David

Joshua, Anthony M.

Gurney, Howard

Wu, Helen

Schloss, Charles

Poehlein, Christian Heinrich

Yu, Evan Y.

机构：

[1] Auckland City Hosp, Auckland, New Zealand

[2] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany

[3] Univ Calif Los Angeles, Los Angeles, CA USA

[4] Gustave Roussy Canc Campus, Villejuif, France

[5] Univ Paris Sud, Villejuif, France

[6] Duke Univ, Sch Med, Cary, NC USA

[7] Inst Curie, Paris, France

[8] Royal Marsden Hosp, London, England

[9] Studienpraxis Urol, Nurtingen, Germany

[10] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[11] Univ Western Ontario, Brampton, ON, Canada

[12] Princess Margaret Canc Ctr, Toronto, ON, Canada

[13] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[14] UCL, Inst Canc, London, England

[15] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[16] Macquarie Univ Hosp, Sydney, NSW, Australia

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.5010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5010

引用

页数：2